Full Year 2023 Investor Presentation
118
Investor presentation Full year 2023
EMEA at a glance
EMEA
Million
300
Diabetes trend
Diabetes market by value and Novo
Nordisk market share
Novo Nordisk reported sales
I
19%
I
I
I
200
I
DKK
billion
25%
150
Full year 2023
MS
Sales
(mDKK)
Growth²
Injectable GLP-13
16,493
28%
100%
RybelsusⓇ
4,232
151%
80%
Total GLP-1
20,725
42%
100
GLP-1
I
36.7%1
Total insulin4
18,287
3%
60%
Other Diabetes care5
260
661
-4%
Insulin
100
195
2.1%1
40%
Diabetes care
39,673
20%
158
50
Obesity care
5,693
63%
20%
OAD
13.1%1
Diabetes & Obesity
0
2021
45,366
24%
0
0%
care
Nov
2030
2045
2018
Nov
2023
Rare disease7
5,501
-19%
Population with diabetes
Diabetes growth rate
Total
50,867
17%
-GLP-1 MS
-Insulin MS
OAD MS
Diabetes trend estimates based on the following International Diabetes Foundation
defined regions: Africa, Europe, Middle East and North Africa, South and Central
America, South East Asia and Western Pacific Source: International Diabetes
Federation: Diabetes Atlas 10th Edition 2021; EMEA: Europe, Middle East and Africa
1 CAGR calculated for 5-year period; Competitor insulin value market shares, as of Nov
2023: Novo Nordisk 48%, Others 52%; Competitor GLP-1 value market shares, as of
Nov 2023: Novo Nordisk 65%, Others 35%. OAD: Oral anti-diabetic; MS: Market share;
Note: Market values are based on the list prices; Source: IQVIA MAT, Nov 2023 value
figures
2 At Constant exchange rates; 3 Comprises Victoza®, OzempicⓇ;
4 Comprises TresibaⓇ, XultophyⓇ, Levemir®, RyzodegⓇ, NovoMix®, FiaspⓇ and
NovoRapidⓇ: 5 Comprises Novo NormⓇ and needles; 6 Obesity care comprises
SaxendaⓇ and Wegovy: 7 Comprises primarily Novo SevenⓇ, NovoEight®
NovoThirteenⓇ, Esperoct®, Refixia®, Norditropin®, Vagifem® and ActivelleⓇView entire presentation